With the ever-increasing number of drugs approved to treat @entity5 , selection of the optimal treatment regimen for an individual @entity1 is challenging. @entity0 complexity requires novel predictive methods and tools. In the present study, we set up experimental conditions to obtain an 'ex  vivo' organotypic culture from xenotransplanted @entity19 aiming at recapitulating the @entity1 clinical condition. The effect of trastuzumab (large biological molecule) and @entity1205 (small chemical entity) was subsequently investigated on this organotypic model and compared with in  vivo and in  vitro activity on @entity5 cells. Tissue slices of 200    m were obtained from mammary fat pad of @entity915 @entity19 xenotransplanted with @entity1 MCF-7 @entity0 cells. Viability and proliferation were evaluated by @entity2454 ( @entity98 ) colorimetric assay and Ki-67 immunohistochemistry,and apoptosis by cleaved caspase-3 immunohistochemistry. In  vivo antitumor activity of trastuzumab and @entity1205 was determined by caliper measurement of @entity5 volume and Ki-67 expression on explanted masses by immunohistochemistry. A Teflon support and normoxia were necessary experimental conditions to obtain high viability of excised @entity0 infiltrated mammary fat pad slices upon 48  h cultivation, as shown by @entity98 proliferation assay, and Ki-67 expression. @entity0 tissue slices treated for 48  h with trastuzumab or @entity1205 showed a significant dose  -dependent reduction of viability by @entity98 assay. Consistently, both drugs down-modulated Ki-67 and increased cleaved caspase-3. Tumor masses collected from @entity1205 - or trastuzumab  -treated @entity19 showed a similar reduction of proliferation markers. By contrast, MCF-7 cell cultures were significantly inhibited by @entity1205 but not by trastuzumab. Tumor tissue slices represent a more predictive experimental @entity5 model compared to cell cultures for both small and large molecule antitumor efficacy. This observation supports the relevance of microenvironment in the overall @entity5 biology and response to therapeutics.

Trastuzumab and @entity1205 in a preclinical organotypic XXXX model using tissue slices from mammary fat pad: Translational relevance.

@entity1 :: ('9606', 'Species') :: ['human', 'patient'] @entity0 :: ('MESH:D001943', 'Disease') :: ['Breast cancer', 'breast cancer'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer'] @entity19 :: ('10090', 'Species') :: ['mice'] @entity915 :: ('MESH:D053632', 'Disease') :: ['SCID'] @entity98 :: ('CHEBI:53233', 'Chemical') :: ['MTT'] @entity2454 :: ('MESH:C022616', 'Chemical') :: ['3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
